Aspire Biopharma Holdings (ASBP) Long-Term Investments (2022 - 2024)

Aspire Biopharma Holdings (ASBP) has reported Long-Term Investments for 3 consecutive years, with $6.7 million the latest figure, recorded in Q4 2024.

• In Q4 2024, Long-Term Investments fell 66.49% year-over-year to $6.7 million; the TTM figure through Dec 2024 stood at $6.7 million (down 66.49% YoY), while the FY2024 annual figure was $6.7 million, down 66.49% from the prior year.
• Long-Term Investments improved to $6.7 million in Q4 2024 per ASBP's latest filing, from $6.5 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $302.2 million in Q1 2023 and bottomed at $6.5 million in Q2 2024.
• Historically, Long-Term Investments has averaged $143.7 million across 3 years, with a median of $20.1 million in 2024.
• On a YoY basis, Long-Term Investments climbed as much as 2.54% in 2023 and fell as far as 93.37% in 2023.
• Aspire Biopharma Holdings' Long-Term Investments stood at $299.0 million in 2022, then tumbled by 93.34% to $19.9 million in 2023, then slumped by 66.49% to $6.7 million in 2024.
• Business Quant data shows ASBP's Long-Term Investments at $6.7 million in Q4 2024, $6.5 million in Q2 2024, and $20.1 million in Q1 2024.